¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11
±³À°ÀÏÀÚ : 2019-08-11
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ´ë°­´ç  
±³À°ÁÖÁ¦ : KGOG 2019 Summer Workshop Cervical Cancer
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : KGOG
¿¬¶ôó : 02-512-5420  
À̸ÞÀÏ : koreagynonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 30,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 08:55~09:00 Orientation  ±è´ë¿¬(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:00~09:10 KGOG ÀڱðæºÎ¾Ï ÀÓ»ó½ÃÇè º¸°í  ±è´ë¿¬(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:10~09:20 NRG, GCIG ÀڱðæºÎ¾Ï ÀÓ»ó½ÃÇè º¸°í  ±è¹®È«(¿øÀÚ·ÂÀÇÇпø) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:20~09:40 2018 Revised FIGO staging: impact on clinical practice  ³ëÁÖ¿ø(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:40~10:00 The updates in early cervical cancer treatment  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:00~10:20 The updates in locally advanced cervical cancer treatment  ¹é¹ÎÇö(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:20~10:40 The updates in recurrent, metastatic cervical cancer treatment  À̼ºÁ¾(°¡Å縯ÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:40~10:50 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:00~11:30 Current status of clinical trials in JGOG  TBD(Japan) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:30~11:50 Current status of translational research in JGOG  TBD(Japan) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:50~12:00 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 13:40~14:00 Current status of clinical trial using by BLS-ILB-E710c (HPV 16 E7 Ag-expressing L. casei vaccine) in patients with CIN 2/3.  ¼Û½ÂÈÆ(Â÷ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:00~14:20 Clearance of persistent HPV infection and cervical lesion by GX-188E (therapeutic DNA vaccine) in CIN3 patients  (Genexine) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:20~14:40 Clinical trial tropical EGCG (Veregen¢ç) targeting cervical dysplasia and HPV infection: UWCCC Chemoprevention Consortium of US-NCI  ÀÌ¿µÀç(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:40~14:50 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:10~15:30 Recent updates in cervical cancer immunotherapy  ¹Ú¿µÇÑ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:30~15:50 Real world experience of Pembrolizumab for cervical cancer patients  ÃÖ¹Îö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:50~16:10 iRECIST: A clarification of tumour response assessment in the immunotherapy era  ±è°æ¿ø(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:10~16:20 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:20~16:30 CX1902 Àç¹ß¼º, ÁøÇ༺, ÀüÀ̼º ÀڱðæºÎ¾Ï¿¡¼­ Ç×¾ÏÁ¦-¾Æ¹Ù½ºÆ¾ º´ÇÕ¿ä¹ýÀÇ ¾ÈÀü¼º ¹× È¿°úÆò°¡¸¦ À§ÇÑ ´Ù±â°ü ÈÄÇâÀû ÄÚȣƮ ±¸Ãà ¿¬±¸  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:30~16:35 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:35~16:45 CX1903 MIS vs Open Surgery in Early cervical cancer Study (MOSES)  ¹ÚÁ¤¿­(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:45~16:50 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:50~17:00 CX1904 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIIC  ³ëÁÖ¿ø(µ¿±¹ÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:00~17:05 Discussion  () 
±³À°½Ã°£ 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:05~17:15 CX1905 Korean radical Tachelectomy of cerviX cancer assessment study (KTX)  ±èÁÖÇö(¿ï»êÀÇ´ë) 
Åä·Ð 08-11 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:15~17:20 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Â÷ÀÇ°úÇдëÇб³ºÎ¼Ó±¸¹ÌÂ÷º´¿ø ½ÉÇ÷°ü¼¾ÅÍ ¿¬¼ö°­Á : 2019-08-16
´ÙÀ½±Û Á¦2ȸ ´ëÇÑ°©»ó¼±µÎ°æºÎ¿Ü°úÇÐȸ ÃÊÀ½ÆÄ¿öÅ©¼¥ : 2019-08-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20515 ¼¼Á¾ Ç÷°üÁßÀç½Ã¼ú¿¬±¸È¸ 2024 K-VIS(Korea Vascular Intervention Society) Annual Symposium : 2024-05-17 0 16 2024-04-29
20514 ¼­¿ï ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-µÑ°³¯ : 2024-05-17 0 10 2024-04-29
20513 ºÎ»ê Á¦54Â÷ ´ëÇѼҾƳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-17 0 29 2024-04-29
20512 ºÎ»ê ´ëÇÑ»êºÎÀΰúÇÐȸ Á¦70Â÷ »êºÎÀΰú ¿¬¼ö°­Á ¹× ¹ßÀü¸ðÀÓ : 2024-05-17 0 15 2024-04-29
20511 ¼­¿ï ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-ù°³¯ : 2024-05-16 0 18 2024-04-29
20510 ºÎ»ê ´ëÇѺñ´¢ÀÇÇÐȸ 310ȸ Çмú´ëȸ(Àü¸³¼± ¾Ï) : 2024-05-16 0 27 2024-04-29
20509 ¼­¿ï Á¦ 21 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-15 0 29 2024-04-29
20508 ¼­¿ï (2ÀÏÂ÷) ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ 2024³â Ãá°è½ÉÆ÷Áö¾ö : 2024-05-14 0 10 2024-04-29
20507 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°ú ºÎ»ê․¿ï»ê․°æ³²Áöȸ Á¦361Â÷ ¿ù·ÊÇмúȸ : 2024-05-14 0 13 2024-04-29
20506 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-¼­¿ï(°­³²) : 2024-05-14 0 16 2024-04-29
20505 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø Æó ¿¬¼ö°­Á : 2024-05-14 0 13 2024-04-29
20504 ¼­¿ï (1ÀÏÂ÷) ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ 2024³â Ãá°è½ÉÆ÷Áö¾ö : 2024-05-13 0 20 2024-04-29
20503 ´ëÀü Çѱ¹¿©ÀÚÀÇ»çȸ ´ëÀüÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö(¾î±ú ÅëÁõÀÇ ¿øÀΰú Ä¡·á) : 2024-05-13 0 16 2024-04-29
20502 °æ±â (¿Â¶óÀÎ) Á¦1Â÷ ±ºÆ÷½ÃÀÇ»çȸ Çмú´ëȸ : 2024-05-12 0 31 2024-04-29
20501 ¼­¿ï Á¦12ȸ ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-12 0 30 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷